[2]
Hussan KH. Nanoemulsion as a novel transdermal drug delivery system. Int J Pharm Sci Res 2011; 2(8): 1938-46.
[3]
Lachman L, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy. Edition 3. 510-1. 2018.
[4]
O’Hagan DT. Vaccine Adjuvant Humana Press. 214.
[6]
Thakur A, Walia MK, Kumar SLH. Nanoemulsion in enhancement of bioavailability of poorly soluble drugs: A review. An Int Res J 2013; 4(1): 15-25.
[7]
Montserrat Roca F, Leverkusen DE. Nanoemulsion. United States
patent application 20090324727 Assignee: Biofrontera Bioscience
Gmbh (Leverkusen, De).
[8]
Arunkumar N, Deecaraman M, Rani C. Nanosuspension technology and its applications in drug delivery. Asian J Pharmaceut 2007; 124: 110.
[9]
Pey CM, Maestro A, Solè I, González C, Solans C, Gutierrez JM. Optimization of nano emulsions prepared by low energy emulsification methods at constant temperature using experimental designs. Coll Surf A Physico chem Engg Asp 2006; 288: 144-50.
[14]
Singh BP, Kumar B, Jain SK, Shafaat K. Development and characterization of a nanoemulsion gel formulation for transdermal delivery of carvedilol. Int J Drug Devpt Res 2012; 4(1): 151-61.
[17]
Devarajan V, Ravichandran V. Nanoemulsions: As modified drug delivery tool. Int J Comprehen Pharm 2011; 4(01): 1-6.
[18]
Patel and Joshi. An overview on nanoemulsion: A novel approach. Int J Pharm Sci Res 2012; 3(12): 4640-50.
[19]
Mishra RKumar, Soni GC, Mishra RP. A review article on nanoemulsion. WJ Pharm Sci 2011; 3(9): 258-74.
[20]
Haritha SP. Basha, Rao KP, Chakravarthi V. A brief introduction to methods of preparation, applications and characterisation of nanoemulsion drug delivery system. Ind J Res Pharm Biotech 2013; 1(1): 25-8.
[21]
Feng J, Roch M, Vigolo D, et al. Nanoemulsions obtained via bubble-bursting at a compound interface. Nat Phy 2014; 10(8): 606-12.
[23]
Simonnet JT, Sonneville O, Lagret S. Nanoemulsion based on
oxyethylenated or non-oxyethylatedsorbiton fatty esters, and its use
in the cosmetic, dermatological and/or ophthalmological fields United States patent US6335022B1. 2002.
[24]
Simonnet JT, Sonneville O, Lagret S. Nanoemulsion based on
ethoxylated fatty ethers or on ethoxylated fatty esters, and its use in
the cosmetic, dermatological and/or ophthalmological fields United States patent US6375960. 2002.
[25]
Benita S, Lambert G. Method and composition for dry eye treatment United States patent US6656460. 2003.
[26]
Alloret FL, Sonneville O, Simonnet JT. Nanoemulsion containing nonionic polymers, and its uses United States patent US6998426. 2006.
[27]
Bague S, Philips B, Garrigue JS, Rabinovich-guilatt L, Lambert G. Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential European patent EP1655021. 2008.
[28]
Philips B, Bague S, Rabinovich-guilatt L, Lambert G. Ophthalmic emulsions containing an immunosuppressive agent European patent
EP1809238. 2008.
[29]
Philips B, Bague S, Rabinovich-guilatt L, Lambert G. Ophthalmic emulsions containing prostaglandin European patent EP1827373. 2008.
[30]
Mitra AK, Velagaeti PR, Natesan S. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors United
States patent US0092665. 2009.
[31]
Alexis F, Zhang L, Radovic-Moreno A, et al. Poly (amino acid)
targeting moieties United States patent US20090074828A1. 2009.
[32]
Domb AJ, Avramoff A, Prevzner V. Pro-nanodispersion for the delivery of cyclosporine United States patent US7732404. 2010.
[33]
Mitra AK, Velagaleti PR, Grau UM. Topical drug delivery for
ophthalmic use WO2010144194. 2010.
[34]
Hara HN, Takeuchi HG. Liposome for delivery to posterior segment of eye and pharmaceutical for disease in posterior segment of eye United States patent US20110008421. 2011.
[35]
Bague S, Betty P, Garrigue JS, Guilatt LR, Lambert G. Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential United States patent US8298568. 2012.
[36]
Ketelson HA, Dassanayake NL, Carey TC, Meadows D. Use of nanoparticles as carriers for biocides in ophthalmic compositions United States patent US8097270. 2012.
[37]
Chauhan A, Gulsen D. Ophthalmic drug delivery system United
States patent US8273366. 2012.
[38]
Ravi N. Hydrogel nanocompsites for ophthalmic applications United States patent US8153156B2. 2012.
[39]
Carli F, Baronian M, Schmid R, Chiellini E. Ophthalmic oil-in-water emulsions containing prostaglandins United States patent
US8414904B2. 2013.
[40]
Bell STD, He Q, Potter DE. Intraocular delivery compositions and
methods WO2004050065A1. 2004.
[41]
Sharma PC. A process for the preparation of oral insulin microcapsules Indian Patent 34/MAS/2002. 2002.
[42]
Ecanow B. Oral insulin and a method of making same US Patent
267749. 1990.
[43]
Burnside BA, Mattes CE, Guinness CMMC, Rudnic EM, Belendiuk GW. Oral insulin delivery US Patent 5824638. 1998.
[44]
Arbit E, Abbas R, Goldberg M, Woods TC, Dinn S, Wong V. Oral
insulin therapy US Patent 10500822. 2008.
[45]
Arbit E, Goldberg M, Majuru S. Oral insulin therapies and protocol US Patent 20090253614. 2009.
[46]
Qian Y, Zhang LJ, Wu ZM. Enteric coated capsule containing
cationic nanoparticles for oral insulin delivery US Patent
20130034602. 2013.
[47]
Gold Berg M, Arbit E. Night time oral insulin therapy US Patent
20060178296. 2006.
[48]
Sabetsky V. Oral insulin composition and methods of making and
using there of U.S Patent 20100166855. 2010.
[49]
Zhang J. Biologically active oral preparation that can be site specific
released in colon US Patent 10297527. 2005.
[50]
Gonda I, Rubsamen RM, Farr SJ. Inhaled insulin dosage control
delivery enhanced by controlling total inhaled volume US Patent
950562. 2004.
[51]
Gonda I, Rubsamen RM, Farr SJ. Use of monomeric insulin as a
means for improving bioavailability of inhaled insulin US Patent
792616. 1999.
[52]
Steiner SS, Pohl R. Rapid acting and prolonged acting inhaled
insulin preparation US Patent 20070086925. 2006.
[53]
Schmitke JL, Chen D, Batycky RP, Edwards DA, Hrkach J. Particles
for inhalation having rapid release properties US Patent
20080227690. 2007.
[54]
Brush H, Fu FN, Lipp MM, Chmitke JL. High load particles for
inhalation having rapid release properties US Patent 20070123449. 2006.
[55]
Backstorm KGE, Dahlback CMO, Edman P, Johansson ACB. Therapeutic preparation for inhalation US Patent 09/665585. 2003.
[56]
Patton JS, Foster L, Platz RM. Methodand composition for pulmonary
delivery of Insulin US Patent 821493. 1999.
[57]
Gonda I, Rubsamen RM. Method of delivering insulin lispro US
Patent 069721. 1999.
[58]
Gonda I, Rubsamen RM, Farr SJ. Method of treating a diabetic
patient by aerosolized administration of insulin US Patent 088534. 2000.
[59]
Backstorm KGE, Dahlback CMO, Edman P, Johansson ACB. Process for preparing composition for inhalation US Patent
858122. 1999.
[60]
Modi P. Pharmaceutical composition for buccal and pulmonary
administration comprisingan alkali metal alkyl sulfate and at least 3
micelle-forming compounds US Patent 574504. 2002.
[61]
Modi P. Method for administering insulin to the buccal region US
Patent 09538829. 2006.
[62]
Thompson W, Kelvin L. On the equilibrium of vapour at a curved surface of liquid. Philos Mag 1871; 42: 448-52.
[63]
Devarajan V, Ravichandran V. Nanoemulsions: As modified drug
delivery tool Int J compr pharm 2011; 2(4): 1-6.
[64]
Nakajima HO, Miyuki T. Emulsified composition US patent
5,098,606. 1992.
[65]
Mittal KL, Dinesh O. Adsorption and aggregation of surfactants in solution European patent 0363928 B1. 1994.
[68]
Bhalani VT, Satishchandra SP. Pharmaceutical composition for
cyclosporines US Patent 5858401A. 1999.
[70]
Calvo P, Lopez R, Vila-Jato JL, Alonso MJ. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Col Poly Sci 1997; 275: 46-53.
[71]
Restel S, Cauwet-Martin D. Eur patent appl EP 842652 Al. 1998.
[73]
Ko KT, Needham TE, Zi H. Emulsion formulation of testosterone for nasal administration. J Microencap 1998; 15: 197-205.
[80]
Shenoy DB, Tiwari SB. Nanoemulsion formulations for improved
oral delivery of poorly soluble drugs. 9th annual NSTI nanotechnology
conference and trade show North-Eastern University US.
[81]
Subhashis D, Satayanarayana J, Gampa VK. Nanoemulsion- A method to improve the solubility of lipophilic drugs. Pharmanest- Int J. Adv Pharm Sci 2011; 2: 72-83.
[90]
Tamilvanan S. Submicron emulsions as a carrier for topical (ocular and per-cutaneous) and nasal drug delivery. Ind J Pharm Educ 2004; 38(2): 73-8.
[95]
Sukanya G, Mantry S, Anjum S. Review on nanoemulsions. Int J Innov Pharm Sci Res 2013; 1(2): 192-205.
[97]
Tadros TF, Becher P. Encyclopedia of emulsion technology. New York: Marcel Dekker 1983; 4: pp. 129-285.
[98]
Shaji J, Joshi V. Self-Microemulsifying Drug Delivery System (SMEDDS) for improving bioavailability of hydrophobic drugs and its potential to give sustained release dosage forms. Ind J Pharm Educ 2005; 39(3): 130-5.
[99]
Nakajima H. Industrial applications of microemulsions. New York: Marcel Dekker 1997; 66: pp. 96-44788.
[101]
Solans C, Esquena J, Forgiarini AM, et al. Absorption and Aggregation of Surfactants in Solution. New York: Marcel Dekker 2003; 2003: p. 109.
[102]
Mason TG, Krall AH, Gang H, Bibette J, Weitz DA. Encyclopedia of emulsion technology, edited by P Becher sMarcel Dekker. New York 1996; Vol. 4: p. 299.
[103]
Bhatt P, Madhav S. A detailed review on nanoemulsion drug delivery system. Int J Pharm Sci Res 2011; 2(10): 2482-9.
[104]
Gupta PK, Pandit JK, Kumar A, Swaroop P, Gupta S. Pharmaceutical nanotechnology novel nanoemulsion-high energy emulsification preparation, evaluation and application. Pharm Res 2010; 3: 117-38.